Scientists test 'One-Two Punch' of engineered immune cells and vaccine to fight tough lymphomas
NCT ID NCT05801913
Summary
This early-stage study is testing the safety and feasibility of a two-part treatment for aggressive B-cell lymphomas that have come back or are resistant to standard therapies. Doctors take a patient's own immune cells, engineer them in a lab to better target cancer, and then infuse them back. They also give a vaccine designed to help these engineered cells last longer and work better to prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.